Samia Mora

List of Publications by Year in Descending Order

182 papers	20,709 citations	59 h-index	143 g-index
216 ext. papers	24,873 ext. citations	10.2 avg, IF	6.58 L-index

#	Paper	IF	Citations
182	Managing Atherosclerotic Cardiovascular Risk in Young Adults: JACC State-of-the-Art Review.. *Journal of the American College of Cardiology*, **2022**, 79, 819-836	15.1	3
181	Red blood cell fatty acid patterns from 7 countries: Focus on the Omega-3 index.. *Prostaglandins Leukotrienes and Essential Fatty Acids*, **2022**, 179, 102418	2.8	0
180	Diabetes Mellitus, Race, and Effects of Omega-3 Fatty Acids on Incidence of Heart Failure Hospitalization.. *JACC: Heart Failure*, **2022**, 10, 227-234	7.9	0
179	Exercise-Induced Ventricular Ectopy and Cardiovascular Mortality in Asymptomatic Individuals. *Journal of the American College of Cardiology*, **2021**, 78, 2267-2277	15.1	2
178	Glycosylation and Cardiovascular Diseases. *Advances in Experimental Medicine and Biology*, **2021**, 1325, 307-319	3.6	1
177	Phenotypic and Genotypic Associations Between Migraine and Lipoprotein Subfractions. *Neurology*, **2021**, 97, e2223-e2235	6.5	1
176	SARS2 simplified scores to estimate risk of hospitalization and death among patients with COVID-19. *Scientific Reports*, **2021**, 11, 4945	4.9	11
175	Association of Lipid, Inflammatory, and Metabolic Biomarkers With Age at Onset for Incident Coronary Heart Disease in Women. *JAMA Cardiology*, **2021**, 6, 437-447	16.2	27
174	Branched-Chain Amino Acids and Risk of Breast Cancer. *JNCI Cancer Spectrum*, **2021**, 5, pkab059	4.6	2
173	Fasting status and metabolic health in relation to plasma branched chain amino acid concentrations in women. *Metabolism: Clinical and Experimental*, **2021**, 117, 154391	12.7	2
172	Nonfasting Lipids for All Patients?. *Clinical Chemistry*, **2021**, 67, 41-45	5.5	1
171	Association of obesity indices with in-hospital and 1-year mortality following acute coronary syndrome. *International Journal of Obesity*, **2021**, 45, 358-368	5.5	0
170	Effects of Vitamin D3 Supplementation on Body Composition in the VITamin D and OmegA-3 TriaL (VITAL). *Journal of Clinical Endocrinology and Metabolism*, **2021**, 106, 1377-1388	5.6	2
169	Effect of Marine Omega-3 Fatty Acid and Vitamin D Supplementation on Incident Atrial Fibrillation: A Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2021**, 325, 1061-1073	27.4	16
168	Risk Factors for Premature Myocardial Infarction: A Systematic Review and Meta-analysis of 77 Studies. *Mayo Clinic Proceedings Innovations, Quality & Outcomes*, **2021**, 5, 783-794	3.1	3
167	Sugar-Sweetened Beverage Consumption May Modify Associations Between Genetic Variants in the CHREBP (Carbohydrate Responsive Element Binding Protein) Locus and HDL-C (High-Density Lipoprotein Cholesterol) and Triglyceride Concentrations. *Circulation Genomic and Precision Medicine*, **2021**, 14, e003288	5.2	1
166	Association of Plasma Branched-Chain Amino Acid With Biomarkers of Inflammation and Lipid Metabolism in Women. *Circulation Genomic and Precision Medicine*, **2021**, 14, e003330	5.2	3

165	Effects of Thyroid Function on Hemostasis, Coagulation, and Fibrinolysis: A Mendelian Randomization Study. *Thyroid*, **2021**, 31, 1305-1315	6.2	2
164	Effects of a low-carbohydrate diet on insulin-resistant dyslipoproteinemia-a randomized controlled feeding trial. *American Journal of Clinical Nutrition*, **2021**,	7	7
163	Serum Vitamin D: Correlates of Baseline Concentration and Response to Supplementation in VITAL-DKD. *Journal of Clinical Endocrinology and Metabolism*, **2021**,	5.6	1
162	Assessing the dyslipidemias: to fast or not to fast?. *Current Opinion in Endocrinology, Diabetes and Obesity*, **2021**, 28, 97-103	4	1
161	The association of cardiovascular mortality with a first-degree family member history of different cardiovascular diseases. *Journal of Geriatric Cardiology*, **2021**, 18, 816-824	1.7	
160	Concordance of Cardiovascular Risk Factors and Behaviors in a Multiethnic US Nationwide Cohort of Married Couples and Domestic Partners. *JAMA Network Open*, **2020**, 3, e2022119	10.4	11
159	Effects of a Low-Carbohydrate Diet on Cardiometabolic Risk Factors During Weight-Loss Maintenance: A Randomized Controlled Feeding Trial. *Current Developments in Nutrition*, **2020**, 4, 625-625	2.4	1
158	Habitual Fish Consumption, n-3 Fatty Acids, and Nuclear Magnetic Resonance Lipoprotein Subfractions in Women. *Journal of the American Heart Association*, **2020**, 9, e014963	6	5
157	Quantum approximate Bayesian computation for NMR model inference. *Nature Machine Intelligence*, **2020**, 2, 396-402	22.5	4
156	Comparison of nonfasting and fasting lipoprotein subfractions and size in 15,397 apparently healthy individuals: An analysis from the VITamin D and OmegA-3 TriaL. *Journal of Clinical Lipidology*, **2020**, 14, 241-251	4.9	7
155	Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM. *Atherosclerosis*, **2020**, 294, 46-61	3.1	49
154	Abstract 13479: Association of Plasma Branched Chain Amino Acid With Biomarkers of Inflammation and Lipid Metabolism in Women. *Circulation*, **2020**, 142,	16.7	1
153	Clinical Characteristics and Severity of COVID-19 Disease in Patients from Boston Area Hospitals **2020**,		5
152	Supplementation With Vitamin D and Omega-3 Fatty Acids and Incidence of Heart Failure Hospitalization: VITAL-Heart Failure. *Circulation*, **2020**, 141, 784-786	16.7	21
151	Effects of Supplemental Vitamin D on Bone Health Outcomes in Women and Men in the VITamin D and OmegA-3 TriaL (VITAL). *Journal of Bone and Mineral Research*, **2020**, 35, 883-893	6.3	33
150	Hypothyroidism and Kidney Function: A Mendelian Randomization Study. *Thyroid*, **2020**, 30, 365-379	6.2	11
149	Vitamin D, Marine n-3 Fatty Acids, and Primary Prevention of Cardiovascular Disease Current Evidence. *Circulation Research*, **2020**, 126, 112-128	15.7	25
148	Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. *Clinical Chemistry and Laboratory Medicine*, **2020**, 58, 496-517	5.9	50

147	Circulating branched-chain amino acids and long-term risk of obesity-related cancers in women. *Scientific Reports*, **2020**, 10, 16534	4.9	11
146	Probabilistic identification of saccharide moieties in biomolecules and their protein complexes. *Scientific Data*, **2020**, 7, 210	8.2	4
145	One-Year Effects of Omega-3 Treatment on Fatty Acids, Oxylipins, and Related Bioactive Lipids and Their Associations with Clinical Lipid and Inflammatory Biomarkers: Findings from a Substudy of the Vitamin D and Omega-3 Trial (VITAL). *Metabolites*, **2020**, 10,	5.6	4
144	Anti-Inflammatory HDL Function, Incident Cardiovascular Events, and Mortality: A Secondary Analysis of the JUPITER Randomized Clinical Trial. *Journal of the American Heart Association*, **2020**, 9, e016507	6	8
143	Premature Myocardial Infarction in the Middle East and North Africa: Rationale for the Gulf PREVENT Study. *Angiology*, **2020**, 71, 17-26	2.1	7
142	Association of the Mediterranean Diet With Onset of Diabetes in the Women's Health Study. *JAMA Network Open*, **2020**, 3, e2025466	10.4	6
141	Assessment of the Relationship Between Genetic Determinants of Thyroid Function and Atrial Fibrillation: A Mendelian Randomization Study. *JAMA Cardiology*, **2019**, 4, 144-152	16.2	36
140	The novel inflammatory marker GlycA and the prevalence and progression of valvular and thoracic aortic calcification: The Multi-Ethnic Study of Atherosclerosis. *Atherosclerosis*, **2019**, 282, 91-99	3.1	15
139	Association of Nonfasting vs Fasting Lipid Levels With Risk of Major Coronary Events in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm. *JAMA Internal Medicine*, **2019**, 179, 898-905	11.5	30
138	Postprandial Hypertriglyceridaemia Revisited in the Era of Non-fasting Lipid Profiles: Executive Summary of a 2019 Expert Panel Statement. *Current Vascular Pharmacology*, **2019**, 17, 538-540	3.3	18
137	Thyroid and Cardiovascular Disease: Research Agenda for Enhancing Knowledge, Prevention, and Treatment. *Thyroid*, **2019**, 29, 760-777	6.2	29
136	Thyroid and Cardiovascular Disease Research Agenda for Enhancing Knowledge, Prevention, and Treatment. *Circulation*, **2019**,	16.7	24
135	Group IIA Secretory Phospholipase A, Vascular Inflammation, and Incident Cardiovascular Disease. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2019**, 39, 1182-1190	9.4	12
134	GlycA, a Novel Inflammatory Marker and Its Association With Peripheral Arterial Disease and Carotid Plaque: The Multi-Ethnic Study of Atherosclerosis. *Angiology*, **2019**, 70, 737-746	2.1	13
133	Statistical Workflow for Feature Selection in Human Metabolomics Data. *Metabolites*, **2019**, 9,	5.6	25
132	Perspectives on the Changing Landscape of Measuring Cardiovascular Risk Related to LDL. *Clinical Chemistry*, **2019**, 65, 1487-1492	5.5	3
131	Effects of One Year of Vitamin D and Marine Omega-3 Fatty Acid Supplementation on Biomarkers of Systemic Inflammation in Older US Adults. *Clinical Chemistry*, **2019**, 65, 1508-1521	5.5	11
130	Serum 25-hydroxyvitamin D in the VITamin D and OmegA-3 TriaL (VITAL): Clinical and demographic characteristics associated with baseline and change with randomized vitamin D treatment. *Contemporary Clinical Trials*, **2019**, 87, 105854	2.3	13

129	Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Narrative Review. *Current Vascular Pharmacology*, **2019**, 17, 515-537	3.3	12
128	Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main Text. *Current Vascular Pharmacology*, **2019**, 17, 498-514	3.3	23
127	Risk factors associated with premature myocardial infarction: a systematic review protocol. *BMJ Open*, **2019**, 9, e023647	3	6
126	GlycA, a novel inflammatory marker, is associated with subclinical coronary disease. *Aids*, **2019**, 33, 547-557	3.5	21
125	Association of High-Density Lipoprotein Particles and High-Density Lipoprotein Apolipoprotein C-III Content With Cardiovascular Disease Risk According to Kidney Function: The Multi-Ethnic Study of Atherosclerosis. *Journal of the American Heart Association*, **2019**, 8, e013713	6	5
124	Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. *New England Journal of Medicine*, **2019**, 380, 33-44	59.2	662
123	Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer. *New England Journal of Medicine*, **2019**, 380, 23-32	59.2	438
122	Directed Non-targeted Mass Spectrometry and Chemical Networking for Discovery of Eicosanoids and Related Oxylipins. *Cell Chemical Biology*, **2019**, 26, 433-442.e4	8.2	35
121	Gene-Based Elevated Triglycerides and Type 2 Diabetes Mellitus Risk in the Women's Genome Health Study. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2019**, 39, 97-106	9.4	5
120	Weighing the Anti-Ischemic Benefits and Bleeding Risks from Aspirin Therapy: a Rational Approach. *Current Atherosclerosis Reports*, **2018**, 20, 15	6	5
119	Markers of Inflammation and Incident Breast Cancer Risk in the Women's Health Study. *American Journal of Epidemiology*, **2018**, 187, 705-716	3.8	28
118	Evaluation of the Pooled Cohort Risk Equations for Cardiovascular Risk Prediction in a Multiethnic Cohort From the Women's Health Initiative. *JAMA Internal Medicine*, **2018**, 178, 1231-1240	11.5	36
117	Circulating Branched-Chain Amino Acids and Incident Cardiovascular Disease in a Prospective Cohort of US Women. *Circulation Genomic and Precision Medicine*, **2018**, 11, e002157	5.2	79
116	Lipoprotein(a) and Cardiovascular Risk Prediction Among Women. *Journal of the American College of Cardiology*, **2018**, 72, 287-296	15.1	48
115	Lipoprotein Particle Profiles, Standard Lipids, and Peripheral Artery Disease Incidence. *Circulation*, **2018**, 138, 2330-2341	16.7	51
114	Adiposity and Genetic Factors in Relation to Triglycerides and Triglyceride-Rich Lipoproteins in the Women's Genome Health Study. *Clinical Chemistry*, **2018**, 64, 231-241	5.5	8
113	Associations of ideal cardiovascular health with GlycA, a novel inflammatory marker: The Multi-Ethnic Study of Atherosclerosis. *Clinical Cardiology*, **2018**, 41, 1439-1445	3.3	17
112	Assessment of Risk Factors and Biomarkers Associated With Risk of Cardiovascular Disease Among Women Consuming a Mediterranean Diet. *JAMA Network Open*, **2018**, 1, e185708	10.4	37

111	Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. *Lancet, The*, **2018**, 392, 1311-1320	40	208
110	Fasting-Evoked En Route Hypoglycemia in Diabetes (FEEHD): An Overlooked Form of Hypoglycemia in Clinical Practice. *International Journal of Endocrinology*, **2018**, 2018, 1528437	2.7	6
109	Altered branched chain amino acid metabolism: toward a unifying cardiometabolic hypothesis. *Current Opinion in Cardiology*, **2018**, 33, 558-564	2.1	19
108	Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM. *Clinical Chemistry*, **2018**, 64, 1006-1033	5.5	124
107	Longitudinal Changes in Cholesterol Efflux Capacities in Patients With Coronary Artery Disease Undergoing Lifestyle Modification Therapy. *Journal of the American Heart Association*, **2018**, 7,	6	3
106	Dietary Intakes and Circulating Concentrations of Branched-Chain Amino Acids in Relation to Incident Type 2 Diabetes Risk Among High-Risk Women with a History of Gestational Diabetes Mellitus. *Clinical Chemistry*, **2018**, 64, 1203-1210	5.5	37
105	Discordance between Circulating Atherogenic Cholesterol Mass and Lipoprotein Particle Concentration in Relation to Future Coronary Events in Women. *Clinical Chemistry*, **2017**, 63, 870-879	5.5	47
104	Effects of statins on the immunoglobulin G glycome. *Biochimica Et Biophysica Acta - General Subjects*, **2017**, 1861, 1152-1158	4	17
103	Association of Air Pollution Exposures With High-Density Lipoprotein Cholesterol and Particle Number: The Multi-Ethnic Study of Atherosclerosis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2017**, 37, 976-982	9.4	44
102	Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin). *Circulation*, **2017**, 135, 2494-2504	16.7	126
101	Impact of Subclinical Hypothyroidism on Cardiometabolic Biomarkers in Women. *Journal of the Endocrine Society*, **2017**, 1, 113-123	0.4	15
100	Genetic associations with lipoprotein subfraction measures differ by ethnicity in the multi-ethnic study of atherosclerosis (MESA). *Human Genetics*, **2017**, 136, 715-726	6.3	9
99	Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol. *Journal of the American Heart Association*, **2017**, 6,	6	70
98	Lipoprotein insulin resistance score and risk of incident diabetes during extended follow-up of 20 years: The Women's Health Study. *Journal of Clinical Lipidology*, **2017**, 11, 1257-1267.e2	4.9	28
97	Association of High-Density Lipoprotein-Cholesterol Versus Apolipoprotein A-I With Risk of Coronary Heart Disease: The European Prospective Investigation Into Cancer-Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and the Women's Health Study. *Journal of the American Heart Association*, **2017**, 6,	6	9
96	Residual Risk of Atherosclerotic Cardiovascular Events in Relation to Reductions in Very-Low-Density Lipoproteins. *Journal of the American Heart Association*, **2017**, 6,	6	43
95	Is it time to abandon fasting for routine lipid testing?. *Cleveland Clinic Journal of Medicine*, **2017**, 84, 919-928	2.82	3
94	Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease: Shared Decision Making in Clinical Practice. *JAMA - Journal of the American Medical Association*, **2016**, 316, 709-10	27.4	25

93	Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease: Advances in Diagnosis and Treatment. *JAMA Internal Medicine*, **2016**, 176, 1195-204	11.5	36
92	Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. *European Heart Journal*, **2016**, 37, 1944-58	9.5	353
91	Nonfasting Sample for the Determination of Routine Lipid Profile: Is It an Idea Whose Time Has Come?. *Clinical Chemistry*, **2016**, 62, 428-35	5.5	15
90	Circulating N-Linked Glycoprotein Acetyls and Longitudinal Mortality Risk. *Circulation Research*, **2016**, 118, 1106-15	15.7	72
89	Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease. *Science*, **2016**, 351, 1166-71	33.3	325
88	Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents. *European Heart Journal*, **2016**, 37, 1373-9	9.5	125
87	Association of N-Linked Glycoprotein Acetyls and Colorectal Cancer Incidence and Mortality. *PLoS ONE*, **2016**, 11, e0165615	3.7	23
86	Fasting for Laboratory Tests Poses a High Risk of Hypoglycemia in Patients with Diabetes: A Pilot Prevalence Study in Clinical Practice. *International Journal of Clinical Medicine*, **2016**, 07, 653-667	0.3	5
85	Shared Decision Making Regarding Aspirin in Primary Prevention of Cardiovascular Disease-Reply. *JAMA - Journal of the American Medical Association*, **2016**, 316, 2276-2277	27.4	
84	Circulating N-Linked Glycoprotein Side-Chain Biomarker, Rosuvastatin Therapy, and Incident Cardiovascular Disease: An Analysis From the JUPITER Trial. *Journal of the American Heart Association*, **2016**, 5,	6	35
83	Fasting Is Not Routinely Required for Determination of a Lipid Profile: Clinical and Laboratory Implications Including Flagging at Desirable Concentration Cutpoints-A Joint Consensus Statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. *Clinical Chemistry*, **2016**, 62, 930-46	5.5	104
82	Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus : Secondary Analysis of a Randomized Clinical Trial. *JAMA Cardiology*, **2016**, 1, 136-45	16.2	38
81	Discordance of Low-Density Lipoprotein and High-Density Lipoprotein Cholesterol Particle Versus Cholesterol Concentration for the Prediction of Cardiovascular Disease in Patients With Metabolic Syndrome and Diabetes Mellitus (from the Multi-Ethnic Study of Atherosclerosis [MESA]). *American Journal of Cardiology*, **2016**, 117, 1921-7	3	31
80	Lipid biomarkers and long-term risk of cancer in the Women's Health Study. *American Journal of Clinical Nutrition*, **2016**, 103, 1397-407	7	84
79	Nonfasting for Routine Lipid Testing: From Evidence to Action. *JAMA Internal Medicine*, **2016**, 176, 1005-6	11.5	31
78	Identifying an Optimal Cutpoint for the Diagnosis of Hypertriglyceridemia in the Nonfasting State. *Clinical Chemistry*, **2015**, 61, 1156-63	5.5	38
77	Reply to Letters Regarding Article, "Prognostic Value of Fasting Versus Nonfasting Low-Density Lipoprotein Cholesterol Levels on Long-Term Mortality: Insight From the National Health and Nutrition Examination Survey III (NHANES-III)". *Circulation*, **2015**, 131, e473	16.7	1
76	Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial. *Circulation*, **2015**, 132, 2220-9	16.7	73

75	Differential Genetic Effects on Statin-Induced Changes Across Low-Density Lipoprotein-Related Measures. *Circulation: Cardiovascular Genetics*, **2015**, 8, 688-95		3
74	Novel protein glycan side-chain biomarker and risk of incident type 2 diabetes mellitus. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2015**, 35, 1544-50	9.4	77
73	Lipoprotein particles and incident type 2 diabetes in the multi-ethnic study of atherosclerosis. *Diabetes Care*, **2015**, 38, 628-36	14.6	84
72	A multivariate genome-wide association analysis of 10 LDL subfractions, and their response to statin treatment, in 1868 Caucasians. *PLoS ONE*, **2015**, 10, e0120758	3.7	118
71	Clinical decisions. The guidelines battle on starting statins. *New England Journal of Medicine*, **2014**, 370, 1652-8	59.2	16
70	Impact of high-dose atorvastatin therapy and clinical risk factors on incident aortic valve stenosis in patients with cardiovascular disease (from TNT, IDEAL, and SPARCL). *American Journal of Cardiology* , **2014**, 113, 1378-82	3	21
69	Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). *Circulation*, **2014**, 129, 635-42	16.7	244
68	Response to letter regarding article, "High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy". *Circulation*, **2014**, 129, e481	16.7	
67	Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. *Journal of the American College of Cardiology*, **2014**, 64, 485-94	15.1	372
66	Safety profile of subjects treated to very low low-density lipoprotein cholesterol levels (. *American Journal of Cardiology*, **2014**, 114, 1682-9	3	44
65	Prognostic value of fasting versus nonfasting low-density lipoprotein cholesterol levels on long-term mortality: insight from the National Health and Nutrition Examination Survey III (NHANES-III). *Circulation*, **2014**, 130, 546-53	16.7	94
64	What's different about women's health?. *Clinical Chemistry*, **2014**, 60, 1-3	5.5	6
63	High-density lipoprotein particle subclass heterogeneity and incident coronary heart disease. *Circulation: Cardiovascular Quality and Outcomes*, **2014**, 7, 55-63	5.8	42
62	Response to letter regarding article, "lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)". *Circulation*, **2014**, 130, e152	16.7	2
61	A novel protein glycan biomarker and future cardiovascular disease events. *Journal of the American Heart Association*, **2014**, 3, e001221	6	133
60	Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events. *Circulation*, **2014**, 129, 553-61	16.7	140
59	Apolipoproteins do not add prognostic information beyond lipoprotein cholesterol measures among individuals with obesity and insulin resistance syndromes: the ARIC study. *European Journal of Preventive Cardiology*, **2014**, 21, 866-75	3.9	14
58	Paradoxical association of lipoprotein measures with incident atrial fibrillation. *Circulation: Arrhythmia and Electrophysiology*, **2014**, 7, 612-9	6.4	48

57	Discovery and refinement of loci associated with lipid levels. *Nature Genetics*, **2013**, 45, 1274-1283	36.3	1904
56	Common variants associated with plasma triglycerides and risk for coronary artery disease. *Nature Genetics*, **2013**, 45, 1345-52	36.3	597
55	Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis. *Circulation*, **2013**, 128, 1504-12	16.7	135
54	Value of reserve pulse pressure in improving the risk stratification of patients with normal myocardial perfusion imaging. *European Heart Journal*, **2013**, 34, 2074-81a	9.5	4
53	High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. *Circulation*, **2013**, 128, 1189-97	16.7	163
52	A comparison of the theoretical relationship between HDL size and the ratio of HDL cholesterol to apolipoprotein A-I with experimental results from the Women's Health Study. *Clinical Chemistry*, **2013**, 59, 949-58	5.5	36
51	On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). *Journal of the American College of Cardiology*, **2012**, 59, 1521-8	15.1	72
50	High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). *Journal of the American College of Cardiology*, **2012**, 60, 508-16	15.1	269
49	Aspirin therapy in primary prevention: comment on "effect of aspirin on vascular and nonvascular outcomes". *Archives of Internal Medicine*, **2012**, 172, 217-8		9
48	A national interactive web-based physical activity intervention in women, evaluation of the american heart association choose to move program 2006-2007. *American Journal of Cardiology*, **2012**, 109, 1754-60	3	17
47	Non-fasting blood testing for lipid screening in children result in statistically significant, but not clinically significant, changes in lipid levels. *Evidence-Based Medicine*, **2012**, 17, 133-4		1
46	Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. *JAMA - Journal of the American Medical Association*, **2012**, 307, 1302-9	27.4	512
45	Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study. *Circulation*, **2012**, 125, 1979-87	16.7	114
44	Fasting for lipid testing: is it worth the trouble?: comment on "fasting time and lipid levels in a community-based population". *Archives of Internal Medicine*, **2012**, 172, 1710-1		20
43	Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. *Journal of Clinical Lipidology*, **2011**, 5, 105-13	4.9	250
42	Association of high-density lipoprotein cholesterol with incident cardiovascular events in women, by low-density lipoprotein cholesterol and apolipoprotein B100 levels: a cohort study. *Annals of Internal Medicine*, **2011**, 155, 742-50	8	39
41	Lipoprotein subclass abnormalities and incident hypertension in initially healthy women. *Clinical Chemistry*, **2011**, 57, 1178-87	5.5	31
40	Lifestyle interaction with fat mass and obesity-associated (FTO) genotype and risk of obesity in apparently healthy U.S. women. *Diabetes Care*, **2011**, 34, 675-80	14.6	65

39	Physical activity attenuates the influence of FTO variants on obesity risk: a meta-analysis of 218,166 adults and 19,268 children. *PLoS Medicine*, **2011**, 8, e1001116	11.6	379
38	Providing patients with global cardiovascular risk information: is knowledge power?. *Archives of Internal Medicine*, **2010**, 170, 227-8		8
37	Lipoprotein(a) and risk of type 2 diabetes. *Clinical Chemistry*, **2010**, 56, 1252-60	5.5	127
36	Exercise blood pressure and future cardiovascular death in asymptomatic individuals. *Circulation*, **2010**, 121, 2109-16	16.7	95
35	Lipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in women. *Diabetes*, **2010**, 59, 1153-60	0.9	115
34	Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. *Circulation*, **2010**, 121, 1069-77	16.7	222
33	The fat-mass and obesity-associated (FTO) gene, physical activity, and risk of incident cardiovascular events in white women. *American Heart Journal*, **2010**, 160, 1163-9	4.9	47
32	HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. *Lancet, The*, **2010**, 376, 333-9	40	178
31	The clinical utility of high-sensitivity C-reactive protein in cardiovascular disease and the potential implication of JUPITER on current practice guidelines. *Clinical Chemistry*, **2009**, 55, 219-28	5.5	73
30	Advanced lipoprotein testing and subfractionation are not (yet) ready for routine clinical use. *Circulation*, **2009**, 119, 2396-404	16.7	71
29	Response to Letter Regarding Article, Fasting Compared With Nonfasting Lipids and Apolipoproteins for Predicting Incident Cardiovascular Events *Circulation*, **2009**, 119,	16.7	3
28	AHA/ACCF [corrected] 2009 performance measures for primary prevention of cardiovascular disease in adults: a report of the American College of Cardiology Foundation/American Heart Association task force on performance measures (writing committee to develop performance measures for primary prevention of cardiovascular disease): developed in collaboration with the	16.7	92
27	Comparison of LDL cholesterol concentrations by Friedewald calculation and direct measurement in relation to cardiovascular events in 27,331 women. *Clinical Chemistry*, **2009**, 55, 888-94	5.5	120
26	Aspirin therapy in women: back to the ABCs. *Circulation: Cardiovascular Quality and Outcomes*, **2009**, 2, 63-4	5.8	5
25	Biphasic pulmonary regurgitation. *Echocardiography*, **2009**, 26, 720-3	1.5	2
24	Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. *Circulation*, **2009**, 119, 931-9	16.7	354
23	ACCF/AHA 2009 performance measures for primary prevention of cardiovascular disease in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for Primary Prevention of Cardiovascular Disease) developed in collaboration with the American Academy of Family Physicians; American Association of Cardiovascular and Pulmonary Rehabilitation; and	15.1	66
22	Use of High-Sensitivity C-Reactive Protein for Risk Assessment **2009**, 158-166 Preventive Cardiovascular Nurses Association: en. *Journal of the American College of Cardiology*, **2009**, 54, 1364-405		

21	Forty-three loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysis. *PLoS Genetics*, **2009**, 5, e1000730	6	265
20	Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *New England Journal of Medicine*, **2008**, 359, 2195-207	59.2	4661
19	The use of high-sensitivity assays for C-reactive protein in clinical practice. *Nature Clinical Practice Cardiovascular Medicine*, **2008**, 5, 621-35		95
18	Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. *Circulation*, **2008**, 118, 993-1001	16.7	289
17	Blood pressure and risk of developing type 2 diabetes mellitus: the Women's Health Study. *European Heart Journal*, **2007**, 28, 2937-43	9.5	129
16	Homocysteine, 5,10-methylenetetrahydrofolate reductase 677C>T polymorphism, nutrient intake, and incident cardiovascular disease in 24,968 initially healthy women. *Clinical Chemistry*, **2007**, 53, 845-51	5.5	53
15	Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. *JAMA - Journal of the American Medical Association*, **2007**, 298, 309-16	27.4	1121
14	LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). *Atherosclerosis*, **2007**, 192, 211-7	3.1	283
13	Physical activity and reduced risk of cardiovascular events: potential mediating mechanisms. *Circulation*, **2007**, 116, 2110-8	16.7	676
12	Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?. *American Journal of Cardiology*, **2006**, 97, 33A-41A	3	156
11	Association of physical activity and body mass index with novel and traditional cardiovascular biomarkers in women. *JAMA - Journal of the American Medical Association*, **2006**, 295, 1412-9	27.4	280
10	Additive value of immunoassay-measured fibrinogen and high-sensitivity C-reactive protein levels for predicting incident cardiovascular events. *Circulation*, **2006**, 114, 381-7	16.7	65
9	Glucose levels in the normal range predict incident diabetes in families with premature coronary heart disease. *Diabetes Research and Clinical Practice*, **2006**, 74, 267-73	7.4	5
8	The metabolic syndrome in women. *Cardiology in Review*, **2006**, 14, 286-91	3.2	73
7	Gender-specific prediction of cardiac disease: importance of risk factors and exercise variables. *Cardiology in Review*, **2006**, 14, 281-5	3.2	14
6	Interaction of body mass index and framingham risk score in predicting incident coronary disease in families. *Circulation*, **2005**, 111, 1871-6	16.7	59
5	Enhanced risk assessment in asymptomatic individuals with exercise testing and Framingham risk scores. *Circulation*, **2005**, 112, 1566-72	16.7	79
4	Ability of exercise testing to predict cardiovascular and all-cause death in asymptomatic women: a 20-year follow-up of the lipid research clinics prevalence study. *JAMA - Journal of the American Medical Association*, **2003**, 290, 1600-7	27.4	361

3	Coronary Artery Disease in Postmenopausal Women. *Current Treatment Options in Cardiovascular Medicine*, **2001**, 3, 67-79	2.1	5
2	Certain cardiac risk factors predict risk factor interventions and influence communication between physicians and patients. *American Journal of Cardiology*, **2000**, 86, 783-5, A9	3	1
1	Branched chain amino acids and risk of breast cancer		1